中国临床药理学与治疗学2026，Vol.31Issue(2)：185-195,11.DOI:10.12092/j.issn.1009-2501.2026.02.006
三氧化二砷血药浓度监测中国专家共识
Chinese expert consensus on blood drug monitoring for arsenic triox-ide
摘要
Abstract
Arsenic trioxide(ATO)is not only a first-line therapy for acute promyelocytic leukemia(APL)but also a widely accepted treatment in other malignancies.However,ATO therapy may lead to suboptimal efficacy or toxic reactions due to its complex active metabolites and significant in-terindividual pharmacokinetic variability.Blood con-centration monitoring,which employs various ana-lytical techniques to determine drug exposure lev-els in vivo,serves as both a fundamental technical approach and a core component of personalized medication.This expert consensus systematically discusses the target population for ATO blood drug monitoring,monitoring indicators,optimal sam-pling times,monitoring recommendations for spe-cial populations,and methodological approaches based on current evidence.The primary objectives are to standardize clinical implementation of blood concentration monitoring in ATO treatment and to advance precision medicine practice.关键词
三氧化二砷/血药浓度/个体化用药/专家共识Key words
arsenic trioxide/blood concentration/personalized medication/expert consensus分类
医药卫生引用本文复制引用
《三氧化二砷血药浓度监测中国专家共识》编写组,高春璐,郭美华,海鑫..三氧化二砷血药浓度监测中国专家共识[J].中国临床药理学与治疗学,2026,31(2):185-195,11.基金项目
国家自然科学基金委员会,面上项目(82274028) （82274028）
黑龙江省重点研发计划(2022ZX02C09) （2022ZX02C09）
黑龙江省自然科学基金重点项目(ZL2024H005) （ZL2024H005）
黑龙江省自然科学基金项目(LH2023H032) （LH2023H032）
黑龙江省卫生健康委科研课题(20241313050032) （20241313050032）
